Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by M. Reck
Targeting KRAS in non-small cell lung cancer: recent progress and new approaches
Highlights • Better understanding of RAS signaling has led to development of promising directly blocking compounds in KRAS mutant tumors • New drug candidates take advantage of the increased knowledge of KRAS mutation complex and relevant protein structures • Increasing evidence continues to demonstrate the genomic heterogeneity in KRAS-mutated NSCLC • Current efforts include understanding and overcoming resistance after treatment with KRASG12C inhibitors Abstract Rat sarcoma (RAS) is the...
437O KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Background: Platinum-based doublet chemo is the standard first-line therapy for advanced NSCLC without a treatable oncogenic aberration. Pembro (anti–PD-1) is approved in the US and EU for previously treated, PD-L1–expressing advanced NSCLC. KEYNOTE-024 (NCT02142738) is an open-label, phase 3 study of pembro vs platinum-doublet chemo as first-line therapy for advanced NSCLC of PD-L1 TPS ?50% without treatable EGFR mutations or ALK translocations.
521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)
Background: Platinum-based chemotherapy (chemo) with etoposide is the current first-line (1L) standard of care for the majority of pts with ES-SCLC. Although initial response rates with chemo range from 50% to 70%, survival outcomes remain poor (median OS, < 1 year), highlighting the need for new treatments.
442O Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057
Background: The CheckMate 057 randomized, open-label, phase III study evaluated the efficacy and safety of nivo vs doc in previously-treated pts with adv NSQ NSCLC. Overall survival was significantly improved with nivo vs doc, as were symptoms as assessed by the Lung Cancer Symptom Scale. Here we report the impact of nivo vs doc on overall pt-reported HS.
A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)
Background: The current standard first-line treatment for the majority of patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) is platinum-based chemotherapy with etoposide. Despite initial response rates ranging from 50% to 70%, median survival remains < 1 year. Atezolizumab (atezo) is an anti-PD-L1 agent that inhibits PD-L1/PD-1 signaling and restores anti-tumor T-cell activity.
Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)
Background: Patients with ED-SCLC have a poor prognosis. We conducted a phase II study to evaluate the efficacy and safety of roniciclib (R), an oral pan-cyclin-dependent kinase inhibitor, in combination with standard first-line platinum-based chemotherapy in subjects with ED-SCLC (NCT02161419).
Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
Background: Current treatments for advanced NSCLC include platinum (plat)-based doublet chemotherapy (chemo), pemetrexed (pem), bevacizumab, targeted drugs and programmed death-ligand 1 (PD-L1)/PD-1–targeted immunotherapy. Atezolizumab (atezo; anti-PDL1) inhibits binding of PD-L1 to PD-1 and B7.1 and restores anti-tumor T-cell activity.
Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057
Background: The CheckMate 057 randomized, open-label, phase III study evaluated the efficacy and safety of nivo vs doc in previously-treated pts with adv NSQ NSCLC. Overall survival was significantly improved with nivo vs doc, as were symptoms as assessed by the Lung Cancer Symptom Scale. Here we report the impact of nivo vs doc on overall pt-reported HS.
NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Background: Nivolumab improves OS compared with docetaxel in previously treated NSCLC. In a phase 1 study (CheckMate 012), nivolumab showed promising activity and manageable safety as monotherapy and in combination with ipilimumab in treatment naive advanced NSCLC. CheckMate 026 (NCT02041533), an open-label, randomized phase 3 study, evaluated the efficacy of nivolumab vs IC PT-DC as first-line therapy in stage IV/recurrent PD-L1–positive NSCLC.
KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
Background: Platinum-based doublet chemo is the standard first-line therapy for advanced NSCLC without a treatable oncogenic aberration. Pembro (anti–PD-1) is approved in the US and EU for previously treated, PD-L1–expressing advanced NSCLC. KEYNOTE-024 (NCT02142738) is an open-label, phase 3 study of pembro vs platinum-doublet chemo as first-line therapy for advanced NSCLC of PD-L1 TPS ?50% without treatable EGFR mutations or ALK translocations.
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer is the most common malignancy after non-melanocytic skin cancer with deaths from lung cancer exceeding those from any other type of malignancy worldwide [1]. While it has been the most important cause of cancer mortality in men since the 1960s, it has equalled breast cancer as a cause of mortality in women since the 1990s. To date, prevention and smoking cessation are still the main methods to reduce the death toll [2].
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with M.
Contact M., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack